JMIR Aging · Nov 20, 2026

AI-Based Monitoring Devices for the Identification of Circadian Parameters as Digital Predictive Biomarkers of Neurodegenerative Diseases in Older Adults: Systematic Review

By Herrera-Zamora JM, Monroy-Rodriguez J, Garcia-Mancilla J et al.

Background: Neurodegenerative diseases such as Alzheimer disease, Parkinson disease, and related dementias are a growing health burden among older adults. Circadian disruption is increasingly recognized as both a consequence and a potential early marker of neurodegenerative progression. Wearable sensing combined with AI enables continuous, noninvasive, and ecologically valid monitoring of circadian parameters as potential digital biomarkers. Objective: This systematic review synthesizes evidence on AI-enhanced wearable and objective sensing devices used to monitor circadian parameters in older and cognitively vulnerable adults and evaluates their potential as digital predictive biomarkers for neurodegenerative diseases. Methods: Following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 guidelines, an original search of PubMed, Scopus, and JMIR journals (June 2025) yielded 12 studies, 7 of which met updated eligibility criteria on rescreening. A complementary search of PubMed, IEEE Xplore, and the ACM Digital Library (March 24, 2026) added 3 eligible studies and 3 sensitivity references (excluded records retained to delimit the corpus boundary). Two reviewers (JMH-Z and JM-R) independently assessed risk of bias with the Mixed Methods Appraisal Tool. Heterogeneous end points precluded meta-analysis; the narrative synthesis covered 4 prespecified domains: device class, circadian construct, AI and machine learning (ML) method family, and population and neurocognitive context. Results: The final corpus comprised 13 records (10 eligible studies and 3 sensitivity references) published from 2015 to 2025. Wrist actigraphy predominated, and samples ranged from community-dwelling older adults to nursing home residents with advanced dementia (n=16-7297). Circadian parameters included interdaily stability, intradaily variability, relative amplitude, midline estimating statistic of rhythm, acrophase, and circadian stimulus. AI/ML methods included supervised learning (random forests, gradient boosting, and regression models), unsupervised clustering, and algorithm development or validation; 7 studies applied deterministic algorithms without fitting a predictive model. Circadian fragmentation was associated with functional decline, dementia risk, and cognitive performance. Most studies were descriptive or observational with small, nondiverse samples; no AI model was externally validated, and no study followed an AI-specific reporting guideline. Conclusions: AI-enhanced wearable devices show meaningful potential for noninvasive measurement of circadian disruption in older and cognitively vulnerable populations. Evidence certainty is moderate for actigraphy-derived fragmentation-function associations in institutional settings and low for predictive biomarker claims in community populations. From 6 recurring challenges along the sensing-to-biomarker pipeline, we propose a 4-layer reference architecture (sensing and acquisition, circadian parameter extraction, AI/ML inference, and a clinical and validation interface) with a layered validation pathway. Longitudinal, multisite validation studies using standardized circadian metrics, diverse populations, and explainable AI remain necessary before clinical deployment as neurodegenerative biomarkers.

doi.org/10.2196/83031PubMed 43063473Biomarkers

AgingResearch.News